247 related articles for article (PubMed ID: 22608310)
1. Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.
Klimek VM; Dolezal EK; Tees MT; Devlin SM; Stein K; Romero A; Nimer SD
Leuk Res; 2012 Sep; 36(9):1093-7. PubMed ID: 22608310
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Cho SH; Lee WS; Joo YD
Ann Hematol; 2013 Jul; 92(7):889-97. PubMed ID: 23420388
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias.
Leone G; Teofili L; Voso MT; Lübbert M
Haematologica; 2002 Dec; 87(12):1324-41. PubMed ID: 12495905
[TBL] [Abstract][Full Text] [Related]
4. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
5. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
6. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).
Bally C; Thépot S; Quesnel B; Vey N; Dreyfus F; Fadlallah J; Turlure P; de Botton S; Dartigeas C; de Renzis B; Itzykson R; Fenaux P; Adès L
Leuk Res; 2013 Jun; 37(6):637-40. PubMed ID: 23499498
[TBL] [Abstract][Full Text] [Related]
8. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine.
Kim DY; Lee JH; Lee JH; Lee KH; Kim YK; Ahn JS; Kim HJ; Kim I; Yoon SS; Park S; Bae SH; Bang SM; Lee HG; Shin HJ; Lee JH; Min YH; Won JH; Mun YC; Oh D;
Ann Hematol; 2010 Jan; 89(1):15-23. PubMed ID: 19543727
[TBL] [Abstract][Full Text] [Related]
9. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
[TBL] [Abstract][Full Text] [Related]
10. Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program.
Musto P; Maurillo L; Spagnoli A; Gozzini A; Rivellini F; Lunghi M; Villani O; Aloe-Spiriti MA; Venditti A; Santini V;
Cancer; 2010 Mar; 116(6):1485-94. PubMed ID: 20151429
[TBL] [Abstract][Full Text] [Related]
11. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
Itzykson R; Fenaux P
Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
[TBL] [Abstract][Full Text] [Related]
12. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
Kantarjian H; Issa JP; Rosenfeld CS; Bennett JM; Albitar M; DiPersio J; Klimek V; Slack J; de Castro C; Ravandi F; Helmer R; Shen L; Nimer SD; Leavitt R; Raza A; Saba H
Cancer; 2006 Apr; 106(8):1794-803. PubMed ID: 16532500
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.
Steensma DP; Stone RM
Hematol Oncol Clin North Am; 2010 Apr; 24(2):389-406. PubMed ID: 20359633
[TBL] [Abstract][Full Text] [Related]
14. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
15. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
16. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
17. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.
Silverman LR; Mufti GJ
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S12-23. PubMed ID: 16341236
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment.
Yi JH; Huh J; Kim HJ; Kim SH; Kim SH; Kim KH; Do YR; Mun YC; Kim H; Kim MK; Kim HJ; Kim T; Kim DD
Ann Hematol; 2013 Apr; 92(4):459-69. PubMed ID: 23262795
[TBL] [Abstract][Full Text] [Related]
19. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
20. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]